p53-based immunotherapy of cancer

Advances in Oto-Rhino-Laryngology

Volumn 62, Issue , 2005, Pages 134-150

  De Leo, Albert B ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; PROTEIN P53;

COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METHODOLOGY; MORTALITY; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL RATE; T LYMPHOCYTE;

CANCER VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16644385562     PISSN: 00653071     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (76)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics. CA Cancer J Clin 2001;51:15-36.
2. Rosenberg SA: Shedding light on immunotherapy for cancer. N Engl J Med 2004;350:1461-1463.
3. Toes RE, Ossendorp F, Offringa R Melief CJ: CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-756.
4. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368.
5. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
6. Rotzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J, Jung G, Rammensee HG: Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990;348:252-254.
7. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-296.
8. Renkvist N, Castelli C, Robbins PF, Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
9. De Leo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ: Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 1979;76:2420-2424.
10. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-408.
11. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eschwege F, Soussi T: Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1228-1233.
12. Soussi T: p53 antibodies in the sera of patients with various types of cancer: A review. Cancer Res 2000;60:1777-1788.
13. Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, Melief CJ: Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995;72:637-641.
14. Van der Burg SH, de Cock K, Menon AG, Franken KL, Palmen M, Redeker A, Drijfhout J, Kuppen PJ, van de Velde C, Erdile L, Tollenaar RA, Melief CJ, Offringa R: Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur J Immunol 2001;31:146-155.
15. Harris CC: Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-1455.
16. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC: Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation. Nucleic Acids Res 1996;24:141-146.
17. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
18. Oliver M, Eeles R, Hollstein M, Khah MA, Harris CL, Hainanut P: TP53 Database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-614.
19. Hauser U, Balz V, Carey TE, Grenman R, van Lierop A, Scheckenbach K, Bier H: Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 2002;24:868-873.
20. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H: Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003;63:1188-1191.
21. Nijman HW, van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ: p53, a potential target for tumor-directed T cells. Immunol Lett 1994;40:171-178.
22. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, De Leo AB: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-1365.
23. Sogn JA: Tumor immunology. The glass is half full. Immunity 1998;9:757-763.
24. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A: Cancer immunotherapy with peptide-based vaccines. What have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805-818.
25. Acres B, Beverley P, Scholl S: Tumor immunology and the battle of Waterloo. Mol Cancer Ther 2002;1:651-655.
26. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA: Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-841.
27. Hernandez J, Lee PP, Davis MM, Sherman LA: The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol 2000;164:596-602.
28. Khong HT, Restifo NP: Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002;3:999-1005.
29. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting. From immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
30. Vierboom MP, Nijman HW, Offringa van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997;186:695-704.
31. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, van der Burg SH, Offringa R, Melief CJ: Antitumor efficacy of wild-type p53-specific CD4+ T-helper cells. Cancer Res 2002;62:6187-6193.
32. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S: SYFPEITHI Database for MHC ligands and peptide motifs. Immunogenetics 1999:50:213-219.
33. Ropke M, Hald J, Guldberg P, Zeuthen J, Norgaard L, Fugger L, Svejgaard A, van der Burg S, Nijman HW, Melief CJ, Claesson MH: Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci USA 1996;93:14704-14707.
34. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA: Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995;92:11993-11997.
35. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J: Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998;160:328-333.
36. Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL, De Leo AB: Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999;5:1281-1288.
37. Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL, De Leo AB: A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res 2000;6:979-986.
38. McArdle SE, Rees RC, Mulcahy KA, Saba J, McIntyre CA, Murray AK: Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. Cancer Immunol Immunother 2000;49:417-425.
39. Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH, Zeuthen J: Cytotoxic T-lymphocyte clones, established by stimulation with the HLA- A2 binding p5365-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol 2000;51:128-133.
40. Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanovic S, Rammensee HG: Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 2000;30:2216-2225.
41. Wurtzen PA, Pedersen LO, Poulsen HS, Claesson MH: Specific killing of p53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted p53-specific CTL line. Int J Cancer 2001;93:855-861.
42. Theobald M, Ruppert T, Kuckelkorn U, Hernandez J, Haussler A, Ferreira EA, Liewer U, Biggs J, Levine AJ, Huber C, Koszinowski UH, Kloetzel PM, Sherman LA: The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 1998:188:1017-1028.
43. Vierboom MP, Zwaveling S, Bos GMJ, Ooms M, Krietemeijer GM, Melief CJ, Offringa R: High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 2000;60:5508-5513.
44. McKaig RG, Baric RS, Olshan AF: Human papillomavirus and head and neck cancer: Epidemiology and molecular biology. Head Neck 1998;20:250-265.
45. Lane DP, Hall PA: MDM2 - Arbiter of p53's destruction. Trends Biochem Sci 1997;22:372-374.
46. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
47. 264-272 peptide in cancer patients: Implications for immunoselection of epitope loss variants. J Immunol 2000;165:5938-5944.
48. 264-272 epitope. J Immunol 2002;168:1338-1347.
49. 264-272 peptide in the circulation of patients with head and neck cancer. Cancer Res 2002;62:3521-3529.
50. Boehncke WH, Takeshita T, Pendleton CD, Houghten RA, Sadegh-Nasseri S, Racioppi L, Berzofsky JA, Germain RN: The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. J Immunol 1993;150:331-341.
51. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997;57:4570-4577.
52. Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G: A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: Implication for more effective immunotherapy. Cancer Res 1999;59:301-306.
53. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM: Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000;13:529-538.
54. Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH: Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol 2001;53:357-364.
55. Casares N, Lasarte JJ, de Cerio AL, Sarobe P, Ruiz M, Melero I, Prieto J, Borras-Cuesta F: Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 2001;31:1780-1789.
56. Wang L, Miyahara Y, Kato T, Aota T, Kuribayashi K, Shiku H: Essential roles of tumor-derived helper T cell epitopes for an effective peptide-based tumor vaccine. Cancer Immun 2003;3:16.
57. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M, Kayibanda M, et al: Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 1995;25:1765-1769.
58. Fujita H, Senju S, Yokomizo H, Saya H, Ogawa M, Matsushita S, Nishimura Y: Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol 1998;28:305-316.
59. Brusic V, Rudy G, Honeyman G, Hammer J, Harrison L: Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics 1998;14:121-130.
60. 110-124-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 2003;63:3675-3681.
61. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA, Carbone DP: Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res 1994;54:1175-1177.
62. Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, Carbone DP: Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999;117:244-251.
63. Tuting T, De Leo AB, Lotze MT, Storkus WJ: Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or 'self' antigens induce antitumor immunity in vivo. Eur J Immunol 1997;27:2702-2707.
64. Nikitina EY, Chada S, Muro-Cacho C, Fang B, Zhang R, Roth JA, Gabrilovich DI: An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther 2002;9:345-352.
65. Hurpin C, Rotarioa C, Bisceglia H, Chevalier M, Tartaglia J, Erdile L: The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine 1998;16:208-215.
66. Tuting T, Gambotto A, Robbins PD, Storkus WJ, De Leo AB: Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: Studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther 1999;6:629-636.
67. Putzer BM, Bramson JL, Addison CL, Hitt M, Siegel PM, Muller WJ, Graham FL: Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum Gene Ther 1998;9:707-718.
68. Nikitina EY, Clark JI, van Beynen J, Chada S, Virmani AK, Carbone DP, Gabrilovich DI: Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001;7:127-135.
69. McCarty TM, Liu X, Sun JY, Peralta EA, Diamond DJ, Ellenhorn JD: Targeting p53 for adoptive T-cell immunotherapy. Cancer Res 1998;58:2601-2605.
70. Liu X, Peralta EA, Ellenhorn JD, Diamond DJ: Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Cancer Res 2000;60:693-701.
71. Waku T, Fujiwara T, Shao J, Itoshima T, Murakami T, Kataoka M, Gomi S, Roth JA, Tanaka N: Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer. J Immunol 2000;165:5884-5890.
72. Kuball J, Schuler M, Antunes Ferreira E, Herr W, Neumann M, Obenauer-Kutner L, Westreich L, Huber C, Wolfel T, Theobald M: Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther 2002;9:833-843.
73. Van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, van de Velde CJ, Moingeon P, Kuppen PJ, Offringa R, Melief CJ: Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 2002;8:1019-1027.
74. Menon AG, Kuppen PJ, van der Burg SH, Offringa R, Bonnet MC, Harinck BI, Tollenaar RA, Redeker A, Putter H, Moingeon P, Morreau H, Melief CJ, van de Velde CJ: Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther 2003;10:509-517.
75. Herrin V, Behrens RJ, Achtar M, Monahan B, Bernstein S, Brent-Steele T, Whiteside T, Wieckowski E, Berzofsky J, Khleif SN: Wild type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinoma. ASCO Chicago, Ill., USA, 2003, abstract 678.
76. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (Wash DC) 2002;298:850-854.